High-Purity Manganese Dioxide for Pharmaceutical Synthesis
Short Product Description
High-purity manganese dioxide (MnO₂) ≥98% for pharmaceutical synthesis. Ideal for organic oxidation and dehydrogenation reactions requiring consistent reactivity and low impurities. Suitable for research and industrial-scale chemical production.

Technical Specifications
| Property | Typical Range | Unit |
|---|---|---|
| MnO₂ content | 98–99 | % |
| Moisture | ≤0.5 | % |
| Particle size (D50) | 5–20 | μm |
| Loss on ignition | ≤0.5 | % |
| Bulk density | 0.8–1.2 | g/cm³ |
| Impurities (Fe, Al, Pb, Cd) | ≤0.01 | % |
Key Features
Ultra-high purity ≥98% for precise chemical synthesis
Controlled particle size for uniform reaction rates
Low moisture and minimal heavy metal impurities
Stable performance under industrial conditions
Easy to handle and disperse in organic solvents
Applications
Pharmaceutical synthesis – suitable for oxidation and dehydrogenation reactions
Organic chemical reactions – provides consistent reactivity
Research laboratories – ensures reproducible experimental results
Fine chemicals production – low impurity grade prevents side reactions
What Problems Do We Solve?
1. Inconsistent Reaction Selectivity in Alcohol Oxidation
Many pharmaceutical synthesis processes rely on selective oxidation of allylic and benzylic alcohols to aldehydes or ketones. Low-grade MnO₂ often contains mixed oxides and impurities that cause side reactions.
Solution
High-purity MnO₂ provides:
Selective oxidation efficiency >90%
Minimal over-oxidation
Cleaner reaction pathways
This improves yield stability and product purity, which is critical in pharmaceutical intermediate synthesis.
2. Heavy Metal Contamination Risks
Pharmaceutical production must comply with strict impurity limits. Technical-grade manganese dioxide may introduce trace metals such as Fe, Cu, or Pb that can contaminate intermediates.
Solution
High-purity MnO₂ features:
Controlled heavy metal content (typically <50 ppm total impurities)
Reduced risk of contamination in APIs and intermediates
Easier compliance with GMP and regulatory standards
This helps pharmaceutical manufacturers maintain regulatory compliance and product safety.
3. Poor Reproducibility Between Batches
Inconsistent particle size and surface activity in standard MnO₂ grades can lead to unstable reaction kinetics.
Solution
High purity manganese dioxide provides:
Controlled particle size distribution (typically 5–20 µm)
Stable surface activity
Consistent oxidation performance across batches
This ensures reproducible reaction conditions in laboratory and scale-up synthesis.
- 4. Difficult Filtration and Downstream Processing
Some oxidants create soluble residues or difficult purification steps.
Solution
MnO₂ acts as a heterogeneous oxidant:
Solid catalyst easily removed by filtration
Minimal downstream purification
Reduced solvent consumption
This improves process efficiency and reduces operational cost.
5. Over-Oxidation of Sensitive Molecules
Pharmaceutical intermediates often contain sensitive functional groups that can be destroyed by strong oxidants.
Solution
MnO₂ operates under mild reaction conditions (20–60 °C) and shows strong functional group tolerance.
This allows:
Controlled oxidation
Protection of sensitive structures
Higher product purity.
Packaging & Supply
Available in 25 kg, 50 kg, and 500 kg bags
Suitable for export with standard documentation
Bulk and custom packaging upon request
Customization & Technical Support
Particle size and purity adjustable to specific requirements
Full technical support for reaction optimization and scale-up
FAQ
1. What purity level of manganese dioxide is required for pharmaceutical synthesis?
Most pharmaceutical synthesis applications require high-purity MnO₂ above 90–95%, with strict control of heavy metals and other impurities to ensure reaction selectivity and regulatory compliance.
2. What reactions commonly use MnO₂ in pharmaceutical manufacturing?
MnO₂ is widely used for:
Oxidation of allylic alcohols to aldehydes
Oxidation of benzylic alcohols to ketones
Late-stage oxidation in organic synthesis
Preparation of pharmaceutical intermediates
These reactions benefit from MnO₂’s high selectivity and mild conditions.
3. How does particle size affect MnO₂ performance?
Particle size directly affects oxidation efficiency.
Typical specifications:
| Parameter | Typical Range |
|---|---|
| Particle Size (D50) | 5–20 µm |
| Smaller particles | Faster reaction rate |
| Larger particles | Easier filtration |
Most fine chemical producers prefer balanced particle size (~10–15 µm) to optimize both activity and filtration.
4. Can MnO₂ be used as a catalyst or only as an oxidant?
MnO₂ can function as:
Stoichiometric oxidant
Heterogeneous oxidation catalyst
Reaction promoter in organic synthesis
Its dual role makes it valuable in laboratory and industrial pharmaceutical synthesis.
5. Is high-purity MnO₂ suitable for scale-up production?
Yes. High-purity MnO₂ is commonly used from:
laboratory R&D
pilot scale synthesis
industrial pharmaceutical intermediate production
Consistent particle size and purity ensure reliable performance during process scale-up.
You can also check out specifications for these applications:
High-Purity Manganese Dioxide for Pharmaceutical Synthesis

Ultra-high purity Pharmaceutical Grade Manganese Dioxide (MnO₂ ≥ 98%) specifically refined for API synthesis and pharmaceutical intermediates. This premium reagent features extremely low heavy metal content (Fe, Pb ≤ 0.01%) and a controlled particle size (D50 2-10 μm) to ensure high selectivity and consistent yields in sensitive organic oxidation reactions.
Product SKU: MnO2-PHARMA-98
Product Brand: BTL New Material
Product In-Stock: InStock
5